Symbiotec Pharmalab IPO Final Subscription Status
Final subscription data from BSE & NSE with category-wise breakdowns
Subscription (Shares)
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIB | 35,50,608 | 64,33,59,195 | 181.20 |
| NII | 26,62,955 | 20,65,31,340 | 77.56 |
| bNII (>10 Lakh) | 17,75,304 | 15,50,46,495 | 87.34 |
| sNII (2-10 Lakh) | 8,87,651 | 5,14,84,845 | 58.00 |
| Retail | 62,13,562 | 8,47,65,465 | 13.64 |
| Employee Reserved | 33,408 | 5,44,845 | 16.31 |
| TOTAL | 1,24,60,533 | 93,52,00,845 | 75.05 |
Application Breakup
| Category | Reserved | Applications | Times |
|---|---|---|---|
| NII | 12,681 | 9,83,483 | 77.56 |
| bNII (>10 Lakh) | 8,454 | 1,52,006 | 17.98 |
| sNII (2-10 Lakh) | 4,227 | 2,45,166 | 58.00 |
| Retail | 4,14,237 | 56,51,031 | 13.64 |
| Employee Reserved | 2,227 | 36,323 | 16.31 |
| TOTAL | 4,41,826 | 70,68,009 | 16.00 |
Subscription (Crores)
| Category | Offered | Demand | Times |
|---|---|---|---|
| QIB | 350.80 | 63,563.89 | 181.20 |
| NII | 263.10 | 20,405.30 | 77.56 |
| bNII (>10 Lakh) | 175.40 | 15,318.59 | 87.34 |
| sNII (2-10 Lakh) | 87.70 | 5,086.70 | 58.00 |
| Retail | 613.90 | 8,374.83 | 13.64 |
| Employee Reserved | 3.30 | 53.83 | 16.31 |
| TOTAL | 1,231.10 | 92,397.84 | 75.05 |
Day-wise Subscription
End-of-day subscription.
| Day | QIB | NII | bNII | sNII | Retail | Emp. | Total |
|---|---|---|---|---|---|---|---|
| Day 1 24 Aug | 0.37x | 1.10x | 0.82x | 1.66x | 1.00x | 1.65x | 0.85x |
| Day 2 25 Aug | 0.57x | 3.16x | 2.59x | 4.30x | 2.21x | 3.19x | 1.95x |
| Day 3 26 Aug | 0.62x | 12.83x | 11.90x | 14.69x | 5.32x | 6.21x | 5.59x |
| Day 4 27 Aug | 181.20x | 77.56x | 87.34x | 58.00x | 13.64x | 16.31x | 75.05x |
Estimated Allotment Chance
How Symbiotec Pharmalab’s demand compares with recent Mainboard IPOs
Final multiples against the 111 Mainboard IPOs listed in the last 12 months.
| Category | Symbiotec Pharmalab | Mainboard median | Higher than |
|---|---|---|---|
| Overall | 75.05x | 20.43x | 74% of 111 |
| QIB | 181x | 21.91x | 81% of 111 |
| NII (HNI) | 77.56x | 22.76x | 66% of 110 |
| Retail | 13.64x | 7.85x | 59% of 106 |
Of the 15 recent Mainboard IPOs that finished 50x–100x subscribed, 93% opened above the issue price, with a median listing-day move of +18.8%. Symbiotec Pharmalab itself listed at +0%.
Symbiotec Pharmalab IPO Subscription — Detailed Analysis
Where Symbiotec Pharmalab Subscription Finished
Symbiotec Pharmalab IPO was subscribed 75.05 times overall by the close of bidding — a heavily oversubscribed level that signals strong investor demand.
Symbiotec Pharmalab IPO Subscription — FAQs
See also: reading the subscription table · allotment chances · allotment process
Explore More
Quick links to all IPO sections